494 Phase 1 dose escalation and dose expansion study of an agonist redirected checkpoint (ARC) fusion protein, SL-279252 (PD1-Fc-OX40L), in subjects with advanced solid tumors or lymphomas

• David Hong,
• Lini Pandite,
• Patrick Schöffski,
• Lilian Siu,
• Melissa Johnson,
• Louis Gonzalez,
• Bo Ma,
• Robert Hernandez,
• Fatima Rangwala,
• Vladimir Galvao,
• Irene Brana

Affiliations

David Hong

1MD Anderson Cancer Center, Houston, TX, USA

Lini Pandite

Aff80 Adaptimmune Philadelphia PA USA

Patrick Schöffski

Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium

Lilian Siu

2Princess Margaret Cancer Centre, Toronto, Canada

Melissa Johnson

3Sarah Cannon Research Institute, Nashville, TN, USA

Louis Gonzalez

Shattuck Labs, Durham, NC, USA

Bo Ma

Shattuck Labs, Durham, NC, USA

Robert Hernandez

Shattuck Labs, Durham, NC, USA

Fatima Rangwala

Shattuck Labs, Durham, NC, USA

Vladimir Galvao

1Hospital Universitari Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Barcelona, Spain

Irene Brana

5Vall d’Hebron Institute of Oncology, Barcelona, Spain